Back from the brink: a mesenchymal stem cell infusion rescues kidney function in acute experimental rhabdomyolysis

Systemic administration of mesenchymal stem (stromal) cells (MSCs) has shown benefit in a range of experimental models of acute kidney injury, although the reported mechanisms of action and requirement for…

Continue ReadingBack from the brink: a mesenchymal stem cell infusion rescues kidney function in acute experimental rhabdomyolysis

Combining Bone Marrow Stromal Cells with Green Tea Polyphenols Attenuates the Blood-Spinal Cord Barrier Permeability in Rats with Compression Spinal Cord Injury

This study was performed to investigate the effect of bone marrow stromal cells (BMSCs) combined with green tea polyphenols (GTPs) on the blood-spinal cord barrier (BSCB) permeability after spinal cord…

Continue ReadingCombining Bone Marrow Stromal Cells with Green Tea Polyphenols Attenuates the Blood-Spinal Cord Barrier Permeability in Rats with Compression Spinal Cord Injury

Noninvasive intranasal stem cells bypass the blood-brain barrier to target the brain to treat Parkinson’s disease, stroke, MS, brain tumors, cerebral ischemia, Alzheimer’s and other CNS disorders

Together with my collaborators in Germany, especially Lusine Danielyan M.D., we discovered and patented (1) that therapeutic cells, including adult stem cells and genetically-engineered cells, can be non-invasively delivered to…

Continue ReadingNoninvasive intranasal stem cells bypass the blood-brain barrier to target the brain to treat Parkinson’s disease, stroke, MS, brain tumors, cerebral ischemia, Alzheimer’s and other CNS disorders

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

Background More than half of patients with multiple sclerosis have progressive disease characterised by accumulating disability. The absence of treatments for progressive multiple sclerosis represents a major unmet clinical need.…

Continue ReadingAutologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study